Analysts’ Recent Ratings Changes for Accuray (ARAY)

Accuray (NASDAQ: ARAY) has recently received a number of price target changes and ratings updates:

• 12/20/2025 – Accuray was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/15/2025 – Accuray had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Accuray had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Accuray had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Accuray had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Accuray had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Accuray had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Accuray was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/6/2025 – Accuray had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a “buy” rating on the stock.

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.